Citigroup’s Immuneering IMRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMRX
S
VCM
OCM
Citigroup's IMRX Position: Q1 2026 in Review
Citigroup increased its Immuneering (IMRX) stake by 7.7% in Q1 2026, buying an estimated $14.8K and bringing the position to 40,417 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #3979.
Citigroup first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $247K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.
- Citigroup held 40,417 shares of Immuneering worth $213K as of Q1 2026.
- Citigroup bought 2,880 Immuneering shares in Q1 2026, an estimated $14.8K.
- Immuneering made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3979 holding.
- Citigroup first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
- Citigroup's Immuneering position peaked at $247K in Q4 2025.
- 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.